Losty Torres Potter, MD
Endocrinology, Diabetes & Metabolism · Sioux City, IANPI 1619358603
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 48.8% of the total.
Across 39 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$485
- Lilly USA, LLC$163
- Medtronic$144
- Dexcom, Inc.$57
- Insulet Corporation$52
- BETA Bionics, Inc.$48
- plus $46 from 3 others
What the payments were for
- Food & beverage$995100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $485 |
| Lilly USA, LLC | 4 | $163 |
| Medtronic(2 entities) | 8 | $144 |
| Dexcom, Inc. | 4 | $57 |
| Insulet Corporation | 3 | $52 |
| BETA Bionics, Inc. | 2 | $48 |
| Novo Nordisk | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$995 in reported general payments places this provider in the 70th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
See all endocrinology, diabetes & metabolism providers in Iowa →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 114 | $157,825 |
| MounjaroTirzepatide | 129 | $149,307 |
| Tresiba Flextouch U-200Insulin Degludec | 85 | $98,445 |
| JardianceEmpagliflozin | 70 | $78,112 |
| FarxigaDapagliflozin Propanediol | 99 | $75,995 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $52,592 |
| TrulicityDulaglutide | 43 | $47,563 |
| TymlosAbaloparatide | 17 | $44,111 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $27,667 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $22,976 |
| Novolog FlexpenInsulin Aspart | 84 | $17,641 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $16,695 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $14,836 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $8,347 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 24 | $6,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $163 | $199,034186 claims |
| Novo NordiskOzempic, Novolog | $17 | $159,725125 claims |
| AstraZenecaFarxiga | $12 | $75,99599 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
Other endocrinology, diabetes & metabolism in Sioux City
- Mary FigaroDavenport$73K
- Ayotunde DokunIowa City$31K
- Anuj BhargavaDes Moines$30K
- Marcelo CorreiaIowa City$10K
- Thomas OdorisioIowa City$7K
- Teck KhooDes Moines$6K
- Rami AlmokayyadAmes$3K
- Amie OgunsakinIowa City$2K
- Fnu DeepikaWaterloo$2K
- Joseph DillonIowa City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.